Optimizing care from the ER to the living room
The Meep system quantifies ADAMTS-13 activity at central lab precision in less than 30 minutes. This allows an immediate rule-out of TTP in suspected Thrombotic Microangiopathies (TMA) in acute care, and enables proactive relapse monitoring for chronic patients at home.
Rapid TMA triage
TMAs are a medical emergency that does not adhere to laboratory schedules. Whether in a general hospital or a reference center, Meep enables immediate, single-sample ADAMTS-13 quantification at any time of day or night. This ensures that critical treatment decisions are never delayed by workflow limitations.
Precise TTP follow-up
Up to 37% of TTP patients experience a relapse, often preceded by a silent, immune-mediated drop in ADAMTS-13 enzyme activity. Meep’s home monitoring solution catches a decrease in ADAMTS-13 activity before it progresses into organ failure. The system automatically alerts the clinician, allowing for expedited therapeutic intervention that prevents an acute TMA hospitalization.
ADAMTS-13 quantification
Meep's advanced photonics chip technology enables real-time detection of ADAMTS-13 activity, delivering accuracy and precision that matches today's leading clinical laboratory analyzers.
Optimized clinical work flow
Clinical & operational impact
Optimize patient flow & capacity
Prevent unnecessary patient transfers and preserve specialized ICU capacity for confirmed TTP cases.
Accelerate time to therapy
Enable immediate risk stratification and rapid initiation of life-saving therapy, including TPE and Caplacizumab.
24/7 test availability
An on-demand solution ensuring expert-level diagnostics are accessible nights, weekends, and holidays.
Prevent readmission
Home monitoring enables timely intervention within critical therapeutic windows, preventing relapse and re-hospitalization.